Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- Galderma Aims at No. 1 Position in Dermatology
September 28, 2009
- Liraglutide Reduces HbA1c More Significantly Than Sitagliptin: Novo Nordisk
September 28, 2009
- Taisho to Acquire BMSs Indonesian Subsidiary
September 28, 2009
- WG to Conduct Clinical Trials to Determine Ethnic Differences among Asians
September 28, 2009
- Caduet to Target Patients Untreated for Hypertension or Hypercholesterolemia
September 28, 2009
- 9th Kitasato Harvard Symposium
September 28, 2009
- Deep Valley of Death Ahead of Japanese Bioventures: Mr Yoshida
September 28, 2009
- R&D CARE NEWS IN BRIEF
September 28, 2009
- Proposed Acquisition of Sepracor by DSP Solves Both Parties Problems
September 28, 2009
- JMA Calls For Periodical Vaccination Programs for Hib, HPV
September 28, 2009
- 6 Mediceo Paltac Subsidiaries to Merge on Oct. 1
September 28, 2009
- Koroshos WG Presents Recommendation on Use of Antipsychotics
September 28, 2009
- da Vinci Surgical System, V.A.C. ATS Treatment System Recommended for Approval
September 21, 2009
- FDG-PET Test for Pediatric Tumors Recommended for Approval as Advanced Healthcare Service
September 21, 2009
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
September 21, 2009
- Korosho's Proposal Regarding Vaccination against New-Type Flu Acceptable
September 21, 2009
- GSK Enters Urology Market with Avolve
September 21, 2009
- Healthcare Providers to Be Preferentially Vaccinated against New-Type Flu
September 21, 2009
- Asahi Kasei Aims at Sales of ¥100 Bil. in FY2015
September 21, 2009
- Chugai to Import Tamiflu for Additional 12 Mil. Persons
September 21, 2009
ページ
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Adeno-associated virus (AAV) gene therapies have long been viewed as carrying only a minimal risk of insertional mutagenesis — a…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…